TNNI3K Antibody (H-7): sc-514417
- TNNI3K Antibody (H-7) is a mouse monoclonal IgG1 κ TNNI3K antibody provided at 200 µg/ml
- raised against amino acids 14-313 mapping near the N-terminus of TNNI3K of human origin
- TNNI3K Antibody (H-7) is recommended for detection of TNNI3K of mouse, rat and human origin by WB, IP, IF and ELISA
- Anti-TNNI3K Antibody (H-7) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for TNNI3K Antibody (H-7) for WB applications. These reagents are now offered in bundles with TNNI3K Antibody (H-7) (see ordering information below).
QUICK LINKS
SEE ALSO...
TNNI3K Antibody (H-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects TNNI3K of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TNNI3K (H-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TNNI3K, also known as TNNI3-interacting kinase or cardiac ankyrin repeat kinase, is a 936 amino acid serine/threonine-protein kinase predominantly expressed in cardiac tissue. TNNI3K enhances cardiac contractility and responsiveness to stress hormones like epinephrine, which is crucial for maintaining heart function during increased physiological demands. TNNI3K plays a protective role by suppressing phosphorylation of cardiac troponin I and inhibiting p38/JNK-mediated apoptosis, thereby safeguarding myocardium from ischemic damage. Research has shown that TNNI3K administration in models of myocardial infarction significantly improves cardiac performance and mitigates ventricular remodeling, highlighting potential as a therapeutic target for cardiac diseases. TNNI3K exists in four isoforms due to alternative splicing, which may contribute to diverse regulatory roles in cardiac physiology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TNNI3K Antibody (H-7) References:
- Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I. | Zhao, Y., et al. 2003. J Mol Med (Berl). 81: 297-304. PMID: 12721663
- Hearts of this ILK rely on TNNI3K, a MAPKKK that regulated TNNI3. | Luft, FC. 2003. J Mol Med (Berl). 81: 279-80. PMID: 12836637
- AOP-1 interacts with cardiac-specific protein kinase TNNI3K and down-regulates its kinase activity. | Feng, Y., et al. 2007. Biochemistry (Mosc). 72: 1199-204. PMID: 18205602
- Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. | Kaski, JP., et al. 2008. Heart. 94: 1478-84. PMID: 18467357
- Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury. | Lai, ZF., et al. 2008. Am J Physiol Heart Circ Physiol. 295: H708-16. PMID: 18552163
- Upregulated expression of cardiac ankyrin repeat protein in human failing hearts due to arrhythmogenic right ventricular cardiomyopathy. | Wei, YJ., et al. 2009. Eur J Heart Fail. 11: 559-66. PMID: 19359327
- Tnni3k modifies disease progression in murine models of cardiomyopathy. | Wheeler, FC., et al. 2009. PLoS Genet. 5: e1000647. PMID: 19763165
- TNNI3K could be a novel molecular target for the treatment of cardiac diseases. | Lai, ZF. 2009. Recent Pat Cardiovasc Drug Discov. 4: 203-10. PMID: 19925440
- Genetic association analysis of coronary heart disease by profiling gene-environment interaction based on latent components in longitudinal endophenotypes. | Gu, CC., et al. 2009. BMC Proc. 3 Suppl 7: S86. PMID: 20018082
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TNNI3K Antibody (H-7) | sc-514417 | 200 µg/ml | $316.00 | |||
TNNI3K Antibody (H-7): m-IgG Fc BP-HRP Bundle | sc-531117 | 200 µg Ab; 10 µg BP | $354.00 | |||
TNNI3K Antibody (H-7): m-IgGκ BP-HRP Bundle | sc-524716 | 200 µg Ab, 40 µg BP | $354.00 | |||
TNNI3K Antibody (H-7) AC | sc-514417 AC | 500 µg/ml, 25% agarose | $416.00 | |||
TNNI3K Antibody (H-7) HRP | sc-514417 HRP | 200 µg/ml | $316.00 | |||
TNNI3K Antibody (H-7) FITC | sc-514417 FITC | 200 µg/ml | $330.00 | |||
TNNI3K Antibody (H-7) PE | sc-514417 PE | 200 µg/ml | $343.00 | |||
TNNI3K Antibody (H-7) Alexa Fluor® 488 | sc-514417 AF488 | 200 µg/ml | $357.00 | |||
TNNI3K Antibody (H-7) Alexa Fluor® 546 | sc-514417 AF546 | 200 µg/ml | $357.00 | |||
TNNI3K Antibody (H-7) Alexa Fluor® 594 | sc-514417 AF594 | 200 µg/ml | $357.00 | |||
TNNI3K Antibody (H-7) Alexa Fluor® 647 | sc-514417 AF647 | 200 µg/ml | $357.00 | |||
TNNI3K Antibody (H-7) Alexa Fluor® 680 | sc-514417 AF680 | 200 µg/ml | $357.00 | |||
TNNI3K Antibody (H-7) Alexa Fluor® 790 | sc-514417 AF790 | 200 µg/ml | $357.00 |